Flag of the European Union EU Clinical Trials Register Help

Clinical trials for TIA

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    182 result(s) found for: TIA. Displaying page 1 of 10.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2013-001185-41 Sponsor Protocol Number: POINT Start Date*: 2013-11-26
    Sponsor Name:University of California San Francisco Stroke Sciences Group
    Full Title: Platelet-Oriented Inhibition in New TIA and minor ischemic stroke (POINT) Trial, a randomized, double blind, multicentre clinical trial
    Medical condition: Transient Ischemic Attack and Minor Stroke
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10068644 Brain stem stroke PT
    14.1 10029205 - Nervous system disorders 10044390 Transient ischaemic attack PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) ES (Completed) DE (Prematurely Ended) FI (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-006749-42 Sponsor Protocol Number: 31350 Start Date*: 2009-01-09
    Sponsor Name:University of Nottingham
    Full Title: Safety and efficacy of clopidogrel when added to aspirin and dipyridamole in high risk patients with recent ischaemic stroke or TIA: a randomised controlled trial
    Medical condition: Ischaemic stroke and TIA (transient ischaemic attack)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10042244 Stroke LLT
    14.1 10029205 - Nervous system disorders 10044390 Transient ischaemic attack PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-005980-26 Sponsor Protocol Number: MAAS Start Date*: 2012-07-04
    Sponsor Name:
    Full Title: Metformin and sitagliptin in patients with impaired glucose tolerance and a recent TIA or minor ischemic stroke - a multicenter, randomized, open-label phase II trial
    Medical condition: Stroke Transient ischemic attack Impaired glucose tolerance
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10042244 Stroke LLT
    14.1 10027433 - Metabolism and nutrition disorders 10052426 Glucose intolerance LLT
    14.1 10029205 - Nervous system disorders 10055221 Ischemic stroke LLT
    14.1 10029205 - Nervous system disorders 10044391 Transient ischemic attacks LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-006971-19 Sponsor Protocol Number: Start Date*: Information not available in EudraCT
    Sponsor Name:Aker universitetssykehus
    Full Title: Effect of Aggrenox® / Asasantin® Retard compared with Clopidogrel on Endothelial function as measured by Microalbuminuria, Inflammatory markers CRP, MCP-1, and MMP-9 in Patients with Type 2 Diabet...
    Medical condition: Patients with Type 2 Diabetes Mellitus and a history of TIA or stroke.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012613 Diabetes mellitus non-insulin-dependent LLT
    9.1 10023027 Ischaemic stroke NOS LLT
    9.1 10044391 Transient ischemic attacks LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-003959-22 Sponsor Protocol Number: CV006-004 Start Date*: 2016-09-06
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 2, Placebo Controlled, Randomized, Double-Blind, Parallel-Arm Study to Evaluate Efficacy and Safety of BMS-986141 For the Prevention of Recurrent Brain Infarction in Subjects receiving acet...
    Medical condition: Recurrent Brain Infarction in Subjects receiving acetylsalicyl acid (ASA) following Acute Ischemic Stroke or Transient Ischemic Attack
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029205 - Nervous system disorders 10061256 Ischaemic stroke PT
    19.0 10029205 - Nervous system disorders 10044390 Transient ischaemic attack PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-002560-41 Sponsor Protocol Number: 0611 Start Date*: 2017-09-21
    Sponsor Name:University of Leicester
    Full Title: A Calcium channel or Angiotensin converting enzyme inhibitor/Angiotensin receptor blocker Regimen to reduce Blood pressure variability in acute ischaemic Stroke (CAARBS): A Feasibility Trial
    Medical condition: Participants in the trial will have had a transient ischaemic attack (TIA) or an acute ischaemic stroke and will also have hypertension. The trial will investigate the possible treatment of blood p...
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029205 - Nervous system disorders 10060840 Ischaemic cerebral infarction PT
    20.0 10029205 - Nervous system disorders 10061256 Ischaemic stroke PT
    20.0 10029205 - Nervous system disorders 10044390 Transient ischaemic attack PT
    20.0 10047065 - Vascular disorders 10015488 Essential hypertension PT
    20.0 10047065 - Vascular disorders 10020772 Hypertension PT
    20.0 10047065 - Vascular disorders 10020783 Hypertension not adequately controlled LLT
    20.0 10047065 - Vascular disorders 10036695 Primary hypertension LLT
    20.0 10047065 - Vascular disorders 10066860 Uncontrolled hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-005546-23 Sponsor Protocol Number: IRIS:IND#64,622 Start Date*: 2009-11-05
    Sponsor Name:Yale University School of Medicine
    Full Title: The Insulin Resistance Intervention after Stroke Trial A randomized, placebo-controlled trial of pioglitazone, compared with placebo, for prevention of stroke and myocardial infarction after ische...
    Medical condition: Insulin resistance in patients who have had a stroke or transient ischaemic attack
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2022-003573-32 Sponsor Protocol Number: 2022/ABM/01/00027 Start Date*: 2023-12-28
    Sponsor Name:Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu
    Full Title: A randomized, double-blind, placebo-controlled study to evaluate the effect of allopurinol on the risk of cardiovascular events in patients at high and very high cardiovascular risk, including the ...
    Medical condition: hyperuricemia, hypertension, ischemic stroke, intracerebral haemorrhage, TIA, heart failure, peripheral arterial disease, atrial fibrillation, diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    20.1 10027433 - Metabolism and nutrition disorders 10020907 Hyperuricemia LLT
    20.0 10047065 - Vascular disorders 10020772 Hypertension PT
    22.1 10029205 - Nervous system disorders 10061256 Ischaemic stroke PT
    21.1 10029205 - Nervous system disorders 10044390 Transient ischaemic attack PT
    20.0 10007541 - Cardiac disorders 10019279 Heart failure LLT
    20.0 10027433 - Metabolism and nutrition disorders 10012601 Diabetes mellitus PT
    27.1 10007541 - Cardiac disorders 10003658 Atrial fibrillation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-001067-27 Sponsor Protocol Number: 20604 Start Date*: 2022-11-10
    Sponsor Name:Bayer AG
    Full Title: A multicenter, international, randomized, placebo controlled, double-blind, parallel group and event driven Phase 3 study of the oral FXIa inhibitor asundexian (BAY 2433334) for the prevention of i...
    Medical condition: Prevention of ischemic stroke in patients post acute non-cardioembolic ischemic stroke or high-risk transient ischemic attack
    Disease: Version SOC Term Classification Code Term Level
    20.0 10042613 - Surgical and medical procedures 10049165 Cerebrovascular accident prophylaxis PT
    22.1 100000004852 10055221 Ischemic stroke LLT
    20.1 100000004852 10072760 Transient ischemic attack LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned) FI (Trial now transitioned) SE (Trial now transitioned) NO (Trial now transitioned) LT (Trial now transitioned) HU (Trial now transitioned) ES (Trial now transitioned) AT (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned) BE (Trial now transitioned) GR (Trial now transitioned) CZ (Trial now transitioned) NL (Trial now transitioned) PL (Trial now transitioned) LV (Trial now transitioned) PT (Trial now transitioned) BG (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-004505-16 Sponsor Protocol Number: CONVINCE Start Date*: 2016-08-08
    Sponsor Name:University College Dublin
    Full Title: CONVINCE - (COlchicine for preventioN of Vascular Inflammation in Non- CardioEmbolic stroke) – a randomised clinical trial of low-dose colchicine for secondary prevention after stroke
    Medical condition: The prevention of recurrent stroke and coronary events (fatal and non- fatal) after ischaemic stroke and transient ischaemic attack (TIA) not caused by cardiac embolism or other causes unrelated to...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10044376 Transient cerebrovascular events HLT
    20.0 100000004866 10008205 Cerebrovascular embolism and thrombosis HLT
    22.1 10029205 - Nervous system disorders 10023027 Ischaemic stroke NOS LLT
    21.1 100000004866 10051615 Atherosclerotic cardiovascular disease LLT
    20.0 10029205 - Nervous system disorders 10007962 Central nervous system vascular disorders NEC HLT
    20.0 10029205 - Nervous system disorders 10007963 Central nervous system vascular disorders HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) ES (Completed) GB (GB - no longer in EU/EEA) DE (Completed) CZ (Completed) DK (Completed) PT (Completed) BE (Completed) LT (Completed) NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-004232-37 Sponsor Protocol Number: D5134C00003 Start Date*: 2017-12-05
    Sponsor Name:AstraZeneca AB
    Full Title: A Randomised, Double-Blind, Placebo-Controlled, International, Multicentre, Phase III Study to Investigate the Efficacy and Safety of Ticagrelor and ASA Compared with ASA in the Prevention of Strok...
    Medical condition: Ischaemic stroke, transient ischaemic attack
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10061256 Ischaemic stroke PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) CZ (Completed) HU (Completed) BG (Completed) FR (Completed) DE (Completed) ES (Completed) BE (Completed) PL (Completed) SK (Completed) IT (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2017-005029-19 Sponsor Protocol Number: CV010031 Start Date*: 2020-06-09
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Global, Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of BMS-986177, an Oral Factor XIa Inhibitor, for the Prevention of New Ischemic Stroke or New Covert Brain Infarc...
    Medical condition: Ischemic Stroke or Transient Ischemic Attack (TIA)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10044390 Transient ischaemic attack PT
    22.1 10029205 - Nervous system disorders 10061256 Ischaemic stroke PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Completed) ES (Ongoing) SE (Completed) HU (Completed) NO (Completed) FI (Completed) BE (Completed) GB (GB - no longer in EU/EEA) AT (Completed) DK (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-005763-28 Sponsor Protocol Number: PM-C-0225 Start Date*: 2006-10-19
    Sponsor Name:Sanofi-Aventis Groupe
    Full Title: Randomized, double-blind trial comparing the effects of a 3-month clopidogrel regimen, combined with ASA during the first month, versus ASA alone for the acute treatment of patients with TIA or mi...
    Medical condition: the acute treatment of patients with TIA or minor stroke
    Disease: Version SOC Term Classification Code Term Level
    8.1 10008192 HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Prematurely Ended) ES (Completed) AT (Completed) HU (Prematurely Ended) SK (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-005772-41 Sponsor Protocol Number: LIMIT phase 2 version 1.0 Start Date*: 2006-12-05
    Sponsor Name:investigator-driven research: Erasmus MC, Neurovascular Section
    Full Title: LIMIT: Lowering the Incidence of vascular complications with Metformin in patients with Impaired glucose tolerance and a recent TIA or minor ischemic stroke: a phase 2, randomized, controlled trial
    Medical condition: Patients with impaired glucose tolerance and a recent TIA or minor ischemic stroke
    Disease: Version SOC Term Classification Code Term Level
    8.1 10052426 Glucose intolerance LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-003622-29 Sponsor Protocol Number: BAYe4465/IMPACT12198 Start Date*: 2007-06-13
    Sponsor Name:Bayer AG
    Full Title: The ARRIVE Study (Aspirin to Reduce Risk of Initial Vascular Events) - A Randomized, Double-Blind, Placebo Controlled, Multicenter, Parallel Group Study to Assess the Efficacy (Reduction of Cardiov...
    Medical condition: Patients at moderate risk of CHD events (10-20% 10-year CHD risk; approximately 30% 10-year risk of CVD events based on the underlying assumption at study start).
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004852 10072760 Transient ischemic attack LLT
    19.0 100000004852 10042244 Stroke LLT
    19.0 10007541 - Cardiac disorders 10046251 Unstable angina LLT
    19.0 10007541 - Cardiac disorders 10028596 Myocardial infarction PT
    19.0 10018065 - General disorders and administration site conditions 10049993 Cardiac death PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) DE (Completed) IE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-022913-25 Sponsor Protocol Number: DOSE201101 Start Date*: 2011-05-19
    Sponsor Name:
    Full Title: A prospective randomised open label study to determine the best dose escalation sceme of dipyridamol added to acetylsalicylic acid, based on the side-effect headache, in patients starting secondary...
    Medical condition: Stroke
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-001675-32 Sponsor Protocol Number: ARTE Start Date*: 2014-10-20
    Sponsor Name:IUCPQ
    Full Title: Aspirin versus Aspirin + ClopidogRel as Antithrombotic Treatment Following Transcatheter Aortic Valve Implantation with the Edwards Valve. A Randomized Study (the ARTE trial).
    Medical condition: Incidence of death, MI, ischemic stroke/Transient ischemic attack (TIA) or life threatening/major bleeding at 3-month follow-up.
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004849 10013118 Diseases of aortic valve LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-000352-36 Sponsor Protocol Number: HP-ALS-TIA Start Date*: 2020-04-27
    Sponsor Name:Christoffer Laustsen
    Full Title: MRI of neurometabolic impairment in ALS and TIA using hyperpolarized pyruvate
    Medical condition: Amyotrophic lateral sclerosis Transient ischemic attack
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10002026 Amyotrophic lateral sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-001795-30 Sponsor Protocol Number: DU176b-C-E314 Start Date*: 2016-11-11
    Sponsor Name:Daiichi Sankyo, Inc.
    Full Title: Evaluation of Edoxaban in Anticoagulant Naïve Patients with Non-Valvular Atrial Fibrillation (NVAF) and high Creatinine Clearance
    Medical condition: Non-Valvular Atrial Fibrillation (NVAF)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10003658 Atrial fibrillation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) CZ (Completed) EE (Completed) LT (Completed) SK (Completed) DK (Completed) HU (Completed) ES (Completed) BE (Completed) PL (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2012-003895-38 Sponsor Protocol Number: D5134C00001 Start Date*: 2014-02-11
    Sponsor Name:AstraZeneca AB
    Full Title: A randomised, double-blind, multinational study to prevent major vascular events with Ticagrelor compared to Aspirin(ASA) in patients with acute ischaemic stroke or Transient Ischemic Attack (TIA)....
    Medical condition: ischaemic stroke
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004852 10055221 Ischemic stroke LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) SK (Completed) BE (Completed) SE (Completed) DE (Completed) IT (Completed) ES (Completed) BG (Completed) FR (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 12 17:53:36 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA